The starting material for virtually all pharmaceuticals and biologics is a synthetic or chemical. Human plasma-derived therapies are one of the few exceptions. A number of fragile proteins can be ...
CHARLESTON, S.C.--(BUSINESS WIRE)--Plasma Technologies LLC (PlasmaTech), a plasma biologics technology company, announced that its novel human plasma fractionation process has been shown to achieve a ...
The New Times on MSN
RBC explores new use for excess plasma from blood donations
Rwanda is looking at how to make use of surplus plasma from blood donations, with much of it currently not being used in hospitals. In other countries, excess plasma, the liquid part of blood, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results